We have not yet achieved the ability to cure advanced NSCLC with systemic therapy, despite our growing understanding of many of the oncogenic drivers of this disease. Rather, the emergence of drug-tolerant and drug-resistant cells remains the rule, even in the face of increasingly potent ...
Nicolas Girard, MD, PhD, discusses patient-reported outcomes from the LUMINOSITY trial of telisotuzumab vedotin in NSCLC.
New Updates on Targeted Therapy for NSCLC Weinberg: Sotorasib received [FDA] approval in May 2021 for patients with KRAS G12C–[mutated] metastatic NSCLC in the second-line setting or later. Adagrasib is a KRAS G12C inhibitor, but it is not yet approved. In general, [KRAS G12C inhib...
Mechanisms of Acquired Resistance in First-Line Treatment – Amivantamab plus Lazertinib vs. Osimertinib Osimertinib: Evolution of Treatment from Refractory Disease to Prevention of Drivers of Disease Progression A Step Forward in c-Met-Targeted Therapy in NSCLC PD-L1 vs LAG-3 Expression in No...
Vascular disrupting agents: a new class of drug in cancer therapy. AimsTo provide a comprehensive overview of the current state of development of a novel class of anti-cancer drugs, the vascular disrupting agents (VDAs), p... AM Gaya,GJS Rustin - 《Clinical Oncology》 被引量: 335发表: 20...
HER2 targeted therapies in different cancer Breast cancer Antibodies The introduction of HER2-targeted therapy has revolutionized the landscape of breast cancer treatment. The currently approved HER2 monoclonal antibodies (mAb) for breast cancer treatment include trastuzumab and pertuzumab. Trastuzumab (Hercept...
In past studies, KRAS mutations have been reported as a prognostic indicator of poor OS in NSCLC,33, 34, 35 while other studies have demonstrated no difference in response to chemotherapy/targeted therapy or OS.36, 37, 38 Although its true prognostication is somewhat unclear due to the complex...
More recently, the immunotherapy revolution, specifically, the development of immune-checkpoint inhibitors (ICIs), has dramatically altered the NSCLC treatment landscape. Herein, we compare and contrast the clinical development of immunotherapy and oncogene-directed therapy for NSCLC, focusing on the role...
Of 6831 patients in the UCSD institutional PREDICT database, 18 patients with advanced pancreatic cancer who received at least one matched targeted therapy (immunotherapy excluded) were identified (Supplementary Fig.1). At the time of matched therapy initiation, 88.9% (N = 16/18) had metasta...
Finally, we conclude this review with the current body of evidence for targeting TROP-2 as a novel target, potentially of importance in post-targeted therapy scenarios. Keywords: targeted therapies 1; NSCLC 2; lung cancer 3; EGFR 4; ALK 5; KRAS 6; MET 7; HER2 8; RET 9; TROP-2 10...